OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books
Oct 7, 2021 • 18min
Same Day Pegfilgrastim
Dr. Ali McBride joins the Pod to spar over same-day vs. next-day pegfilgrastim. (There is some audio feedback early in the Pod that we clean up after a few minutes. Apologies!)
Bibliography:
Burris et al: https://pubmed.ncbi.nlm.nih.gov/20808556/
AOC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819939/
McBride et al (CHOP): https://www.futuremedicine.com/doi/10.2217/fon-2021-0532
McBride et al (NHL): https://doi.org/10.18553/jmcp.2021.21010
Sep 30, 2021 • 13min
Sarcomas In A Nutshell
An oversimplified approach to thinking about sarcomas.
Sep 23, 2021 • 23min
ESMO21 & New Drugs (Cervical Ca Focus)
Lots to discuss from ESMO 2021 to new drug approvals.
First, we discuss the updates in cervical cancer from ESMO (pembrolizumab with chemo) and the newly approved tisotumab-vedotin.
Then, we discuss another new agent, mobocertinib and its scary QT prolongation profile as well as cabo-confusion in thyroid cancer.
Finally, we discuss the potentially practice changing, but preliminary, data from ESMO in bladder cancer (VESPER) and HER2+ MBC (DESTINY-Breast03).
Sep 16, 2021 • 13min
CASSIOPEIA Part 2
This discussion dives into the pivotal findings of the CASSIOPEIA Part 2 clinical trial, examining the role of daratumumab in treating myeloma after auto stem cell transplant. It tackles the effectiveness of this maintenance therapy and highlights critiques related to the trial's design. The ethical implications of using an observation control group spark thought-provoking debate, making for an engaging exploration of current myeloma treatments.
Sep 9, 2021 • 17min
MMF For ITP
Discussing the use of mycophenolate mofetil (MMF) for ITP (https://www.nejm.org/doi/full/10.1056/NEJMoa2100596) as well as regulatory updates on atezolizumab and zanubrutinib.
Sep 2, 2021 • 10min
Hypercalcemia Of Malignancy (in Under 10)
Foundations of OncoPharm: Hypercalcemia of Malignancy (in under 10 minutes)
Aug 26, 2021 • 17min
Belzutifan and Recent Updates
Belzutifan, the 1st hypoxia-inducible factor (HIF) inhibitor is FDA-approved. Plus, expanded indication approvals for nivolumab, dostarlimab, lenvatinib/pembrolizumab, & Ivosidenib. Finally, my Top 5 Rolling Stones Songs (14:30).
Aug 19, 2021 • 12min
Booster COVID-19 Vaccinations in Immunocompromised Patients
Looking into the data behind the FDA & CDC's allowance for a booster mRNA vaccine for immunocompromised patients.
Aug 12, 2021 • 8min
Sneaky TKI Toxicities
A recent patient experience serves as a reminder than TKIs, like cabozantinib, can produce many "minor" toxicities that can really add up and affect QOL.
Aug 5, 2021 • 12min
Acala V. Ibrutinib(again) & VidazaAllo
Two recent publications to discuss:
1. The publication of a study discussed on our ASCO '21 Pod on acalabrutinib vs. ibrutinib and patient implications (https://ascopubs.org/doi/pdf/10.1200/JCO.21.01210)
2. A good illustration of the "crossing of the curves" and interpreting Kaplan-Meier curves using alloHSCT vs. 5-aza in MDS patients. https://ascopubs.org/doi/pdf/10.1200/JCO.20.02724
